This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Rheinische Friedrich-Wilhelms-Universitat Bonn. Active years: 2013-2014.
Company Filing History:
Years Active: 2013-2014
Title: **The Innovations of Lucas Peters: A Pioneer in GPR17 Agonists**
Introduction
Lucas Peters, an innovative inventor based in Bad Honnef, Germany, has made notable contributions to the field of biochemistry through his patented work. With a total of two patents to his name, Peters is recognized for advancing our understanding of GPR17, a receptor that plays a crucial role in various biological processes.
Latest Patents
Lucas Peters’ latest patents focus on GPR17 agonists and related screening assays. His first patent describes a method for determining a test compound's ability to modify the biological activity of GPR17. This method involves contacting the test compound with GPR17 or a functional GPR17 fragment in the presence of a suitable amount of a GPR17 agonist of a specified formula. The second patent echoes this innovation, reinforcing the importance of GPR17 in biological regulation and pharmacology by detailing similar methodologies for identifying modulators of GPR17.
Career Highlights
Throughout his career, Peters has affiliated himself with esteemed institutions such as Rheinische Friedrich-Wilhelms-Universität Bonn. His time at this prominent university has allowed him to delve deeper into his research interests, particularly in the area of receptor biology and pharmacology. His efforts have greatly contributed to scientific knowledge and have the potential for practical applications in drug development.
Collaborations
Peters has collaborated with notable researchers Evi Kostenis and Andreas Spinrath, key figures in the study of GPR17. These collaborations have enhanced his research endeavors, allowing for a multifaceted approach to understanding GPR17's role in physiological processes and potential therapeutic targets.
Conclusion
In summary, Lucas Peters is a distinguished inventor whose work on GPR17 agonists has paved the way for future innovations in pharmacology. Through his patented methodologies and collaborations, Peters continues to make significant strides in the scientific community, offering promising insights into the modulation of biological activity. His contributions are a testament to the impact inventors can have on advancing research and development in critical areas of health and medicine.